Thursday, October 21, 2021

The Salk Institute and Sanford Burnham Prebys license ULK1/2 inhibitors to Endeavor BioMedicines for treatment of cancer

The Salk Institute and Sanford Burnham Prebys license ULK1/2 inhibitors to Endeavor BioMedicines for treatment of cancerment-of-cancer/

Happy to see that the compounds that we developed at SBP in the Cosford lab and in conjunction with the Shaw lab at Salk are being advanced further into preclinical development and then hopefully on to the clinic to help in the treatment of patients!